Current trials commonly apply methods such as IHC or FISH to determine the existence of MET overexpression, and a further scoring system according to the percentage of tumor cells with high staining intensity is used to stratify MET-positive/high and MET-negative/low patients, although the criteria differ by small degrees. This evidence concerns the gene MET and neoplasm.